| Biological Information | |
|---|---|
| Background Information: | Foretinib (GSK1363089) is a synthetic small anticancer molecule. Potently and ATP-competitively inhibits MET and VEGFR2 (IC50=0.4 and 0.9nM, respectively), kinase enzymes believed to promote tumor growth and angiogenesis. Previously underwent clinical trials for breast cancer and NSCLC but no product made it to market. Provided as 5 mg of dry powder. |
| Target Name: | Foretinib |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
Foretinib (GSK1363089)
Foretinib (GSK1363089) is an binding stabilizer of RIPK2. This product is provided as 5 mg of dry powder.
Datasheets
92-1238 Datasheet
View Document